Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland

Completed

Conditions: Obesity or Overweight

Interventions: Drug: Saxenda®

First Posted Date: 2021-12-10

Last Posted Date: 2022-11-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 269

Registration Number: NCT05153590

Locations: 🇩🇰
Novo Nordisk Investigational Site, Soeborg, Denmark

A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: NNC0480-0389
Drug: Placebo (NNC080-0389)
Drug: Placebo (semaglutide)
Drug: Semaglutide

First Posted Date: 2021-12-06

Last Posted Date: 2024-02-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 500

Registration Number: NCT05144984

Locations: 🇺🇸
First Valley Med Grp Lancaster, Lancaster, California, United States
🇺🇸
Piedmont Healthcare/Research, Statesville, North Carolina, United States
🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States

and more 85 locations

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

Phase 3

Recruiting

Conditions: Haemophilia A and B With and Without Inhibitors

Interventions: Drug: Concizumab

First Posted Date: 2021-11-26

Last Posted Date: 2024-10-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 90

Registration Number: NCT05135559

Locations: 🇺🇸
Children's Nebraska, Omaha, Nebraska, United States
🇺🇸
Rady Childrens Hosp San Diego, San Diego, California, United States
🇺🇸
Arnold Palmer Children's Hospital, Orlando, Florida, United States

and more 81 locations

A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes Pharmacokinetics and Pharmacodynamics: How Insulin NNC0363-0845 is Transported Throughout the Body and How It Works

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: NNC0363-0845
Drug: Insulin detemir

First Posted Date: 2021-11-26

Last Posted Date: 2022-11-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT05134987

Locations: 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity

Phase 3

Completed

Conditions: Overweight and Obesity

Interventions: Drug: semaglutide 50 mg
Drug: placebo (semaglutide)

First Posted Date: 2021-11-24

Last Posted Date: 2024-06-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 201

Registration Number: NCT05132088

Locations: 🇯🇵
Naka Kinen Clinic, Ibaraki, Japan
🇯🇵
ToCROM Clinic, Tokyo, Japan
🇯🇵
Osaka University Hospital, Osaka, Japan

and more 10 locations

A Research Study Looking at New Protein-based Tablets in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Volunteers
High Blood Cholesterol Levels
Type 2 Diabetes

Interventions: Drug: Semaglutide D
Drug: NNC0385-0434 B
Drug: NNC0385-0434 C
Drug: Semaglutide G
Drug: NNC0385-0434 D
Drug: Semaglutide H
Drug: NNC0385-0434 E
Drug: Semaglutide I

First Posted Date: 2021-11-22

Last Posted Date: 2024-05-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 384

Registration Number: NCT05129891

Locations: 🇩🇪
Parexel International GmbH, Berlin, Germany
🇨🇦
Altasciences Company Inc., Montreal, Quebec, Canada

A Research Study of How a New Medicine NNC0365-3769 (Mim8) Works in the Body of Healthy People

Phase 1

Completed

Conditions: Healthy Volunteers - Haemophilia A

Interventions: Drug: Mim8 B, 10 mg/mL
Drug: Mim8 B, 100 mg/mL
Drug: Mim8 B, placebo

First Posted Date: 2021-11-19

Last Posted Date: 2023-11-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 66

Registration Number: NCT05127473

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Research Study Looking Into Levels of the Medicine NNC0385-0434 in the Body and How Well it is Tolerated in Participants With Impaired Kidney Function Compared to Participants With Normal Kidney Function

Phase 1

Terminated

Conditions: Chronic Kidney Disease

Interventions: Drug: NNC0385-0434 A 100 mg

First Posted Date: 2021-10-26

Last Posted Date: 2023-12-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 60

Registration Number: NCT05094934

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers
Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk
Elevated Cholesterol

Interventions: Drug: NNC0385-0434

First Posted Date: 2021-10-25

Last Posted Date: 2023-12-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 73

Registration Number: NCT05091073

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)

Phase 3

Completed

Conditions: Haemophilia A

Interventions: Drug: turoctocog alfa pegol (N8-GP)

First Posted Date: 2021-10-18

Last Posted Date: 2024-12-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT05082116

Locations: 🇨🇳
Beijing Children's Hospital，Capital Medical University, Beijing, Beijing, China
🇨🇳
Fujian Medical University Union Hospital-Hematology, Fuzhou, Fujian, China
🇨🇳
Haemotology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

and more 5 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy